Selank vs Semax: Comparing Two Russian Nootropic Peptides

Selank and Semax are two synthetic peptides that emerged from Soviet and Russian neuropeptide research programs, and they are often discussed together as the core of the so-called "Russian nootropic" category. Both are short chains of seven amino acids (heptapeptides), both are typically administered intranasally, and both were designed by attaching a stabilizing Pro-Gly-Pro tail to a naturally occurring peptide fragment. That shared design philosophy is where much of the confusion between them begins — but their parent molecules, and therefore their primary effects, are quite different.

Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a stabilized analog of tuftsin, a naturally occurring immune-modulating tetrapeptide (Thr-Lys-Pro-Arg). Its full sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, with a molecular formula of C₃₃H₅₇N₁₁O₉ and a molecular weight of roughly 751.88 g/mol. In Russia, Selank has been investigated and used primarily as an anxiolytic — an anti-anxiety agent — for generalized anxiety disorder and related conditions.

Semax is a synthetic analog of a fragment of adrenocorticotropic hormone, specifically ACTH(4-10), again stabilized with a Pro-Gly-Pro tail. Its sequence is Met-Glu-His-Phe-Pro-Gly-Pro, its molecular formula is C₃₇H₅₁N₉O₁₀S (note the sulfur atom from the methionine residue), and its molecular weight is approximately 813.92 g/mol. Unlike full ACTH, Semax was engineered to keep the neurotropic and cognitive effects of the fragment while removing the hormonal (cortisol-releasing) activity. It has been used in Russia for ischemic stroke, transient ischemic attack, cognitive disorders and optic nerve conditions.

It is important to be clear from the outset: neither peptide is approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Outside Russia and a handful of neighboring countries, both are sold and handled as research chemicals, not as medicines. If you are new to this class of compounds, our overview of what peptides are provides useful background before going further.

This article is for educational purposes only and is not medical advice. Always consult a qualified healthcare professional before considering any peptide.

Both peptides are described as regulatory peptides — meaning they nudge existing signaling systems rather than acting like a single-target drug. Because they are small and are usually delivered intranasally, a fraction can reach the central nervous system relatively quickly. Once there, they influence neurotransmitters, growth factors and, in Selank's case, immune signaling. The overlap in some of these pathways is why users sometimes report similar mood benefits, even though the peptides were designed for different purposes.

Semax has been most studied for its effect on brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). In rodent models, Semax increases BDNF and the activity of its receptor TrkB in the hippocampus and basal forebrain — regions central to learning and memory. Semax also appears to modulate the dopaminergic and serotonergic systems and to have neuroprotective and antioxidant effects, which is the rationale behind its use in ischemic (reduced blood flow) brain injury. Genome-wide studies have shown that Semax alters the expression of large sets of genes involved in vascular tone, inflammation and neuroplasticity.

Selank shares the BDNF-modulating and enkephalin-related effects but adds two distinctive mechanisms. First, as a tuftsin analog, it has immunomodulatory activity, influencing cytokines such as interleukin-6 and interferon-related signaling. Second, its anxiolytic action is linked to the GABAergic and serotonergic systems and to changes in the expression of genes tied to the balance of excitatory and inhibitory neurotransmission — producing calm without the sedation or dependence associated with benzodiazepines in the studies conducted.

A shared mechanism worth highlighting is that both peptides appear to slow the breakdown of enkephalins, the body's own opioid-like signaling molecules involved in mood and pain regulation. By inhibiting the enzymes that degrade enkephalins, both Selank and Semax may prolong these calming, mood-stabilizing signals. This shared pathway helps explain why the two compounds are so often grouped together and combined.

An important caveat: the great majority of this mechanistic detail comes from animal and cell studies. Translating a change in rodent hippocampal BDNF to a reliable cognitive benefit in a healthy human is a significant leap, and the human data — discussed below — are far more limited than the mechanistic literature might suggest.

Although Selank and Semax look similar on paper — both heptapeptides, both intranasal, both Russian — their primary uses sit at opposite ends of the calm–stimulation spectrum. The simplest way to frame it: Selank leans toward anxiolysis (calming), while Semax leans toward cognitive activation and neuroprotection (focus and repair). Many users describe Selank as "taking the edge off" and Semax as "turning the lights on."

The table below summarizes the main distinctions:

A second key difference is subjective feel and timing. Semax is frequently described as noticeably activating — some users take it earlier in the day to avoid interference with sleep — while Selank is more neutral or calming and is often used specifically to counter anxiety or overstimulation. This is precisely why the two are combined: one balances the other.

A third difference lies in the strength of the human evidence. Semax has been the subject of Russian clinical work in acute stroke and cognitive impairment, giving it a somewhat larger (though still region-limited) clinical footprint. Selank's human evidence centers on small anxiety and neurasthenia trials. For both, robust, large-scale, placebo-controlled Western trials are essentially absent — a critical limitation when weighing claims.

Finally, because Selank retains tuftsin-derived immune activity, it is sometimes discussed in the context of immune modulation and inflammation, a property Semax does not share in the same way. Semax, conversely, has a more pronounced neurovascular and neurotrophic profile relevant to brain injury.

The evidence base for both peptides is unusual: it is deep in Russian-language preclinical and small clinical literature but thin in the large, blinded, peer-reviewed international trials that Western regulators require. Readers should interpret reported benefits with that asymmetry in mind.

For Semax, the most cited human work comes from Russian studies in acute ischemic stroke, where intranasal Semax administered alongside standard care was associated with improved neurological recovery and reduced functional impairment. Additional Russian studies have examined Semax for cognitive impairment, attention and optic nerve disorders. Mechanistically, the Dolotov and colleagues work demonstrating that Semax raises BDNF protein in the rat basal forebrain is frequently referenced as biological plausibility for cognitive effects. However, these stroke trials are generally small, not always double-blinded, and have not been replicated by independent Western groups.

For Selank, the key clinical reference is the work by Zozulya and colleagues, who reported that Selank was comparable to the benzodiazepine medazepam in patients with generalized anxiety disorder and neurasthenia, but without the sedation, cognitive dulling or withdrawal typically associated with benzodiazepines. Preclinical studies support anxiolytic, antidepressant-like and nootropic effects, along with the immunomodulatory activity expected from a tuftsin analog. Again, sample sizes are modest and independent replication is limited.

Both peptides have been examined together in transcriptomic (gene-expression) studies by groups such as Kolomin and colleagues, which have mapped how each alters expression of genes tied to inflammation, neurotransmission and vascular function. These studies are valuable for understanding mechanism but do not, on their own, establish clinical efficacy in humans.

The honest summary is that both compounds show consistent and biologically plausible signals — anxiolysis for Selank, neuroprotection and cognitive support for Semax — but that the quality and geographic breadth of the evidence fall short of what would be needed for regulatory approval outside Russia. Anyone evaluating these peptides should treat marketing claims of guaranteed cognitive enhancement with skepticism.

Both peptides are almost always used intranasally, typically as a solution delivered in metered drops or sprays. Intranasal delivery is favored because it is non-invasive and may allow some direct nose-to-brain transport, and because both peptides are rapidly broken down in the digestive tract, making oral dosing impractical. Some research protocols use injectable forms, but intranasal is the dominant route in the available literature and among users.

The dosing figures below reflect ranges reported in the literature and by suppliers. They are provided for educational context only and do not constitute a protocol or a recommendation to self-administer:

Because Semax is more activating, users commonly take it earlier in the day, while Selank, being calming, is sometimes used later or specifically during periods of stress or anxiety. Both are typically used in short cycles (for example, one to several weeks) rather than continuously, though formal duration guidance is lacking due to the absence of long-term human safety data.

Reconstitution matters. Peptides such as these are usually supplied as a lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic water and then kept refrigerated. Errors in reconstitution are a common source of inaccurate dosing. Our peptide reconstitution calculator can help translate a target dose into an accurate volume, and readers combining compounds may find our peptide stacking guide useful for sequencing and timing.

Because neither peptide is an approved medicine outside Russia, no regulator has validated a safe and effective dose for general use. Dosing decisions carry real risk and should only be made under professional medical supervision.

Combining Selank and Semax is one of the most common questions about this pair, and it is the logic behind pre-made Semax + Selank blends sold by some suppliers. The theoretical rationale is straightforward and appealing: Semax provides cognitive activation and focus, while Selank counterbalances any overstimulation or anxiety, yielding a "calm, focused" state. Because they act through partly overlapping (BDNF, enkephalin) and partly complementary (dopaminergic activation vs. GABAergic calming) pathways, many users consider them a natural pairing.

That said, the evidence for the combination specifically is weak. Most human data examine each peptide individually; controlled trials of the combined intranasal use in healthy people for cognitive enhancement are essentially absent. So while the pairing is popular and mechanistically plausible, claims about synergy are largely anecdotal or extrapolated from single-agent studies. This is an area where it is easy to overstate what is actually known.

Practically, users who stack them often administer them at different times — for example, Semax in the morning for focus and Selank later to wind down — rather than dosing both simultaneously, precisely because their subjective profiles differ. Others use a fixed-ratio blend for convenience. There is no established evidence that one approach is superior.

If you are considering any combination of research peptides, our guide to peptide stacking covers general principles — starting one compound at a time to isolate effects, keeping accurate records, and understanding that combining compounds also combines their uncertainties and potential side effects. Combining two unapproved research peptides increases, rather than reduces, the unknowns.

Consult a healthcare professional before combining any peptides. The absence of documented interactions is not evidence of safety — it usually reflects the absence of research.

In the available Russian clinical and preclinical studies, both Selank and Semax have generally been reported as well tolerated at the doses studied, with a notably favorable profile compared with conventional anxiolytics or stimulants. Selank, for instance, was reported to lack the sedation, dependence and withdrawal associated with benzodiazepines. However, "well tolerated in small short-term studies" is very different from "proven safe," and no peptide should ever be described as having no side effects.

Reported or plausible side effects are generally mild and include local nasal irritation from intranasal use, mild headache, fatigue or changes in alertness, and — for the activating Semax — possible overstimulation, restlessness or sleep disruption if taken too late in the day. Because Selank has immunomodulatory activity, its long-term effects on immune function have not been well characterized in humans.

The most significant safety limitation is the near-total absence of long-term human data. There is little information on the effects of months or years of use, on interactions with medications, or on use in vulnerable populations such as pregnant or breastfeeding individuals, adolescents, or people with psychiatric or immune conditions. In these groups, the compounds should be considered unstudied and therefore unsuitable.

Product quality is a further, often underestimated risk. Because these are sold as research chemicals, purity, dosing accuracy and sterility vary between suppliers. Contaminated or mislabeled product is a real hazard, particularly for anything administered intranasally or by injection. Third-party testing (certificate of analysis) is the minimum a cautious researcher should look for.

For a fuller discussion of the risks inherent to unapproved peptides, see our medical disclaimer. This section is educational and not a substitute for individualized medical advice; consult a qualified healthcare professional before use.

The regulatory picture is a defining feature of both peptides. In Russia, Selank and Semax are approved medicines for specific indications (anxiety disorders for Selank; stroke and cognitive disorders for Semax). In the United States, European Union and most other jurisdictions, neither is an approved drug or dietary supplement. They are sold — where sold at all — labeled strictly as research chemicals "not for human consumption." Legal status varies by country and can change, so buyers are responsible for understanding their local law.

This research-only status has direct practical consequences. There is no pharmacy-grade supply chain, no regulatory oversight of manufacturing, and no guarantee that a vial contains what its label claims. As a result, sourcing and third-party testing become the most important safety decisions a researcher makes — arguably more important than dosing.

Among suppliers that carry these peptides, availability and pricing differ by region. For reference, some current listings include Selank at SwissChems (5 mg vial, 25.95 USD) and at AminoClub (31.99 USD), and Semax at SwissChems (30 mg vial, 73.95 USD) and at AminoClub (34.99 USD). A pre-made Semax + Selank blend is listed at CertaPeptides (20 mg, 39.99 EUR). Note that AminoClub ships within the US only, SwissChems ships worldwide, and CertaPeptides ships within the EU only. Prices change frequently, so always confirm the current figure on the supplier's own site before relying on it.

When evaluating any source, prioritize a published certificate of analysis confirming identity and purity, transparent manufacturing information, and clear storage and handling guidance. You can compare current listings on our shop page. Beyond price, the questions that matter are purity, testing and legality in your jurisdiction.

Klow Peptide does not encourage the use of unapproved substances. This information is provided for educational purposes only. Consult a qualified healthcare professional and verify the legal status of any peptide in your country before purchasing.